"RIV/00216208:11150/13:10159012" . . "1"^^ . "Farmakoterapie" . "6"^^ . . . "Brentuximab vedotin v l\u00E9\u010Db\u011B Hodgkinova lymfomu a syst\u00E9mov\u00E9ho anaplastick\u00E9ho velkobun\u011B\u010Dn\u00E9ho lymfomu"@cs . "neuropathy; anaplastic large cell lymphoma; classical Hodgin's lymphoma; brentuximab vedotin"@en . "Brentuximab vedotin v l\u00E9\u010Db\u011B Hodgkinova lymfomu a syst\u00E9mov\u00E9ho anaplastick\u00E9ho velkobun\u011B\u010Dn\u00E9ho lymfomu"@cs . . . "1801-1209" . "I, P(NT12193)" . "Belada, David" . . "Brentuximab vedotin v l\u00E9\u010Db\u011B Hodgkinova lymfomu a syst\u00E9mov\u00E9ho anaplastick\u00E9ho velkobun\u011B\u010Dn\u00E9ho lymfomu" . . "Brentuximab vedotin is a chimeric anti-CD30 monoclonal antibody conjugated with microtubule inhibitor monomethyl aurinostat E. Results from a phase II study in relapsed or refractory Hodgkin's lymphoma are very promising: overall response was 75% with 34% of complete responses. In a phase II study in relapsed or refractory CD30-positive systemic anaplastic large cell lymphoma (72% of patients were ALK negative), overall response was 86% with complete response in 57%. Recommended dosing is 1.8 mg/kg i.v. repeated every 3 weeks up to a maximum of 16 cycles. Ongoiong trials in first line, as well as before or after autologous stem cell transplantation in relapsed patients may establish the optimal role of this drug in lymphoma patients. Brentuximab vedotin may become a new milestone in the treatment of relapsed or refractory Hodgkin's lymphoma and CD30-positive non-Hodgkin's lymphoma patients."@en . "Brentuximab vedotin je chim\u00E9rick\u00E1 anti CD30 monoklon\u00E1ln\u00ED protil\u00E1tka s nav\u00E1zan\u00FDm mikrotubul\u00E1rn\u00EDm inhibitorem - monometyl auristatinem E. V\u00FDsledky f\u00E1ze II studie u v\u00FDrazn\u011B p\u0159edl\u00E9\u010Den\u00FDch, relabuj\u00EDc\u00EDch nebo refraktern\u00EDch nemocn\u00FDch s Hodgkinov\u00FDm lymfomem prok\u00E1zaly velmi nad\u011Bjn\u00E9 v\u00FDsledky. Celkov\u00E1 l\u00E9\u010Debn\u00E1 odpov\u011B\u010F byla 75 %, u 34 % bylo dosa\u017Eeno kompletn\u00ED remise. U nemocn\u00FDch s relabuj\u00EDc\u00EDm nebo refraktern\u00EDm syst\u00E9mov\u00FDm anaplastick\u00FDm CD30 pozitivn\u00EDm velkobun\u011B\u010Dn\u00FDm lymfomem (72 % bylo ALK negativn\u00EDch) bylo ve studii f\u00E1ze II dosa\u017Eeno 86% celkov\u00E9 l\u00E9\u010Debn\u00E9 odpov\u011Bdi p\u0159i dosa\u017Een\u00ED 57% kompletn\u00EDch remis\u00ED. Standardn\u00ED d\u00E1vkov\u00E1n\u00ED je 1,8mg/kg v intervalech 3 t\u00FDdn\u016F, maxim\u00E1ln\u011B 16 cykl\u016F l\u00E9\u010Dby. Brentuximab vedotin m\u016F\u017Ee znamenat po dlouh\u00E9 dob\u011B nov\u00FD miln\u00EDk v l\u00E9\u010Db\u011B relabuj\u00EDc\u00EDch nebo refraktern\u00EDch nemocn\u00FDch s Hodgkinov\u00FDm a CD30 pozitivn\u00EDm anaplastick\u00FDm velkobun\u011B\u010Dn\u00FDm nehodgkinov\u00FDm lymfomem." . . . . "63859" . "Brentuximab vedotin in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma patients"@en . "Brentuximab vedotin in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma patients"@en . . "11150" . "CZ - \u010Cesk\u00E1 republika" . . . . "5" . . . "Brentuximab vedotin je chim\u00E9rick\u00E1 anti CD30 monoklon\u00E1ln\u00ED protil\u00E1tka s nav\u00E1zan\u00FDm mikrotubul\u00E1rn\u00EDm inhibitorem - monometyl auristatinem E. V\u00FDsledky f\u00E1ze II studie u v\u00FDrazn\u011B p\u0159edl\u00E9\u010Den\u00FDch, relabuj\u00EDc\u00EDch nebo refraktern\u00EDch nemocn\u00FDch s Hodgkinov\u00FDm lymfomem prok\u00E1zaly velmi nad\u011Bjn\u00E9 v\u00FDsledky. Celkov\u00E1 l\u00E9\u010Debn\u00E1 odpov\u011B\u010F byla 75 %, u 34 % bylo dosa\u017Eeno kompletn\u00ED remise. U nemocn\u00FDch s relabuj\u00EDc\u00EDm nebo refraktern\u00EDm syst\u00E9mov\u00FDm anaplastick\u00FDm CD30 pozitivn\u00EDm velkobun\u011B\u010Dn\u00FDm lymfomem (72 % bylo ALK negativn\u00EDch) bylo ve studii f\u00E1ze II dosa\u017Eeno 86% celkov\u00E9 l\u00E9\u010Debn\u00E9 odpov\u011Bdi p\u0159i dosa\u017Een\u00ED 57% kompletn\u00EDch remis\u00ED. Standardn\u00ED d\u00E1vkov\u00E1n\u00ED je 1,8mg/kg v intervalech 3 t\u00FDdn\u016F, maxim\u00E1ln\u011B 16 cykl\u016F l\u00E9\u010Dby. Brentuximab vedotin m\u016F\u017Ee znamenat po dlouh\u00E9 dob\u011B nov\u00FD miln\u00EDk v l\u00E9\u010Db\u011B relabuj\u00EDc\u00EDch nebo refraktern\u00EDch nemocn\u00FDch s Hodgkinov\u00FDm a CD30 pozitivn\u00EDm anaplastick\u00FDm velkobun\u011B\u010Dn\u00FDm nehodgkinov\u00FDm lymfomem."@cs . "9" . "http://www.farmakoterapie.cz/c3841/brentuximab-vedotin-v-lecbe-hodgkinova-lymfomu-a-systemoveho-anaplastickeho-velkobunecneho-lymfomu" . "RIV/00216208:11150/13:10159012!RIV14-MSM-11150___" . . "Brentuximab vedotin v l\u00E9\u010Db\u011B Hodgkinova lymfomu a syst\u00E9mov\u00E9ho anaplastick\u00E9ho velkobun\u011B\u010Dn\u00E9ho lymfomu" . "1"^^ . . "[D03EBD2E2D04]" .